Source:http://linkedlifedata.com/resource/pubmed/id/11241414
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2001-3-12
|
| pubmed:abstractText |
To assess the prognostic value of CD44s and CD44v6 tumour expression for patients with T1-T2 conventional renal cell carcinomas, a retrospective immunohistochemical analysis of 95 patients was undertaken. These patients had undergone a radical nephrectomy, performed in three institutions in France between 1987 and 1993. The mean age of the patients was 62.9+/-10.2 years (range from 37 to 85 years) with 66.3% males. At the time of surgery, 84 patients had a T1 and 11 a T2 renal tumour. Fuhrman nuclear grading showed 44 (46.3%) tumours of grade 1, 39 (41.1%) of grade 2, and 12 (12.6%) of grade 3. The mean follow-up period was 58.1+/-36.1 months. At the end of follow-up, eight patients (8.4%) had metastatic disease and no local recurrence was seen. Immunohistochemistry showed that 26 tumours (27.4%) expressed CD44s, but none expressed CD44v6. Statistical analysis showed that CD44s expression was correlated with tumour size (p=0.006) and Fuhrman grading (p<10(-4)). Among the various parameters tested for the multivariate analysis, CD44s expression correlated only with disease-free survival (p=0.04). It is concluded that CD44s expression, but not CD44v6, is of potential prognostic interest in patients with localized T1-T2 conventional renal cell carcinomas.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0022-3417
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
193
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
345-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11241414-Adult,
pubmed-meshheading:11241414-Aged,
pubmed-meshheading:11241414-Aged, 80 and over,
pubmed-meshheading:11241414-Antigens, CD44,
pubmed-meshheading:11241414-Antigens, Neoplasm,
pubmed-meshheading:11241414-Carcinoma, Renal Cell,
pubmed-meshheading:11241414-Disease-Free Survival,
pubmed-meshheading:11241414-Female,
pubmed-meshheading:11241414-Follow-Up Studies,
pubmed-meshheading:11241414-Humans,
pubmed-meshheading:11241414-Immunoenzyme Techniques,
pubmed-meshheading:11241414-Kidney Neoplasms,
pubmed-meshheading:11241414-Male,
pubmed-meshheading:11241414-Middle Aged,
pubmed-meshheading:11241414-Multivariate Analysis,
pubmed-meshheading:11241414-Prognosis,
pubmed-meshheading:11241414-Retrospective Studies,
pubmed-meshheading:11241414-Tumor Markers, Biological
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
CD44s and CD44v6 expression in localized T1-T2 conventional renal cell carcinomas.
|
| pubmed:affiliation |
Department of Pathology, CHU Timone, Marseille, France. ldaniel@mail.ap-hm.fr
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|